ACRS Aclaris Therapeutics Inc

Price (delayed)

$14.45

Market cap

$962.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.37

Enterprise value

$926.48M

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The ...

Highlights
Aclaris Therapeutics's quick ratio has increased by 29% QoQ and by 21% YoY
Aclaris Therapeutics's EPS has increased by 14% QoQ and by 2.1% YoY
ACRS's debt has plunged by 94% YoY but it is up by 3.3% from the previous quarter
ACRS's equity has soared by 60% YoY but it is down by 9% QoQ
ACRS's gross profit is down by 14% from the previous quarter
The company's revenue fell by 6% YoY and by 4.8% QoQ

Key stats

What are the main financial stats of ACRS
Market
Shares outstanding
66.58M
Market cap
$962.11M
Enterprise value
$926.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.91
Price to sales (P/S)
137.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
143.93
Earnings
Revenue
$6.44M
EBIT
-$80.9M
EBITDA
-$80.06M
Free cash flow
-$61.34M
Per share
EPS
-$1.37
Free cash flow per share
-$1
Book value per share
$2.94
Revenue per share
$0.1
TBVPS
$3.57
Balance sheet
Total assets
$226.53M
Total liabilities
$46.33M
Debt
$716,000
Equity
$180.2M
Working capital
$174.16M
Liquidity
Debt to equity
0
Current ratio
11.41
Quick ratio
10.78
Net debt/EBITDA
0.45
Margins
EBITDA margin
-1,243.7%
Gross margin
27.5%
Net margin
-1,256.8%
Operating margin
-1,140.3%
Efficiency
Return on assets
-31.4%
Return on equity
-39.1%
Return on invested capital
-45.5%
Return on capital employed
-38.6%
Return on sales
-1,256.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACRS stock price

How has the Aclaris Therapeutics stock price performed over time
Intraday
-8.83%
1 week
-7.43%
1 month
21.22%
1 year
-15.4%
YTD
-0.62%
QTD
-16.18%

Financial performance

How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$6.44M
Gross profit
$1.77M
Operating income
-$73.4M
Net income
-$80.9M
Gross margin
27.5%
Net margin
-1,256.8%
Aclaris Therapeutics's operating margin has plunged by 67% YoY and by 18% from the previous quarter
The operating income has plunged by 57% YoY and by 12% from the previous quarter
ACRS's net margin is down by 34% YoY but it is up by 6% from the previous quarter
The company's net income fell by 26% YoY but it rose by 11% QoQ

Growth

What is Aclaris Therapeutics's growth rate over time

Valuation

What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
4.91
P/S
137.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
143.93
Aclaris Therapeutics's EPS has increased by 14% QoQ and by 2.1% YoY
ACRS's equity has soared by 60% YoY but it is down by 9% QoQ
ACRS's P/B is 59% above its 5-year quarterly average of 3.4 and 12% above its last 4 quarters average of 4.8
The company's revenue fell by 6% YoY and by 4.8% QoQ
ACRS's P/S is 2.5% above its last 4 quarters average of 147.6

Efficiency

How efficient is Aclaris Therapeutics business performance
The company's return on equity has surged by 63% YoY and by 18% QoQ
Aclaris Therapeutics's return on invested capital has surged by 59% YoY and by 17% QoQ
The ROA has soared by 52% YoY and by 17% from the previous quarter
Aclaris Therapeutics's return on sales has decreased by 34% YoY but it has increased by 6% QoQ

Dividends

What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRS.

Financial health

How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's total assets has increased by 40% YoY but it has decreased by 10% from the previous quarter
Aclaris Therapeutics's quick ratio has increased by 29% QoQ and by 21% YoY
ACRS's debt is 100% less than its equity
The debt to equity has dropped by 100% year-on-year
ACRS's debt has plunged by 94% YoY but it is up by 3.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.